MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Cash and Cash Equivalents 2011-2026 | SNOA
Annual Cash and Cash Equivalents Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.37 M | 3.13 M | 3.82 M | 7.4 M | 4.22 M | 3.69 M | 3.69 M | 10.1 M | 17.5 M | 7.47 M | 6.14 M | 5.48 M | 7.9 M | 3.35 M | 4.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.5 M | 3.13 M | 6.24 M |
Quarterly Cash and Cash Equivalents Sonoma Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.56 M | 3.04 M | 3.6 M | 5.37 M | 5.24 M | 4.08 M | 2.59 M | 3.13 M | 2.41 M | 2.14 M | 3.54 M | 3.82 M | 2.63 M | 3.35 M | 5.59 M | 7.4 M | 8.53 M | 8.39 M | 2.81 M | 4.22 M | 5.54 M | 5.54 M | 4.32 M | 4.55 M | 3.73 M | 3.73 M | 3.23 M | 4.28 M | 6.5 M | 6.5 M | 4.05 M | 10.1 M | 8.62 M | 9.98 M | 12.6 M | 17.5 M | 19 M | 3.25 M | 4.97 M | 7.47 M | 6.11 M | 7.97 M | 8.75 M | 6.14 M | 2.24 M | 3.55 M | 4.99 M | 5.48 M | 3.44 M | 3.19 M | 5.38 M | 7.9 M | 6.6 M | 8.31 M | 4.4 M | 3.35 M | 4.96 M | 3.62 M | 5.02 M | 4.37 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19 M | 2.14 M | 5.59 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.89 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 0.97 | 2.36 % | $ 104 M |  Canada |
 |
Aurora Cannabis
ACB
|
138 M | $ 3.31 | 1.53 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
600 K | $ 0.63 | 16.11 % | $ 11 M |  China |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
112 M | $ 8.05 | -1.71 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
4.74 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 3.05 | 7.77 % | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
947 M | $ 5.1 | 1.8 % | $ 1.86 B | Canada |
 |
Harrow Health
HROW
|
72.9 M | $ 34.0 | 2.16 % | $ 1.25 B | USA |
 |
Assertio Holdings
ASRT
|
10.2 M | $ 14.0 | 4.71 % | $ 89.6 M | USA |
 |
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
53.8 M | $ 4.68 | 0.86 % | $ 302 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
277 M | $ 22.65 | 2.44 % | $ 1.05 B | USA |
 |
OrganiGram Holdings
OGI
|
24.6 M | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
9.11 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
349 K | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
3.5 M | $ 5.86 | -3.46 % | $ 231 M | USA |
 |
Rockwell Medical
RMTI
|
8.98 M | $ 1.02 | -2.86 % | $ 23.8 M | USA |
 |
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
252 M | $ 1.36 | 0.74 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
21.3 M | $ 0.88 | -6.09 % | $ 43.9 M | USA |
 |
Solid Biosciences
SLDB
|
59.9 M | $ 7.14 | 1.56 % | $ 625 M | USA |
 |
Organogenesis Holdings
ORGO
|
136 M | $ 2.47 | 3.65 % | $ 325 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
148 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
532 M | $ 9.57 | 3.46 % | $ 1.33 B | USA |
 |
Tilray
TLRY
|
207 M | $ 6.45 | 3.86 % | $ 3.99 B | Canada |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
4.33 M | $ 2.31 | 3.12 % | $ 24.1 M | USA |
 |
Veru
VERU
|
24.9 M | $ 2.3 | 1.32 % | $ 310 M | USA |
 |
Viatris
VTRS
|
992 M | $ 13.29 | 0.68 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
2.45 M | $ 0.76 | 11.88 % | $ 3.28 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | USA |